Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093962 · ClinicalTrials.gov registry record · Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Phase 2 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT02093962: Clinical Trial Phase 2 study, sponsored by ImmunoGenesis.
NCT02093962 is a Phase 2 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 265 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02093962, a Phase 2 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
Primary Outcome
To assess the efficacy of pemetrexed in combination with TH-302 as determined by overall survival in patients with advanced non-squamous NSCLC in the second-line chemotherapy setting compared with pemetrexed in combination with placebo
Interventions
- DRUG TH-302 combination with pemetrexed
- DRUG Matched placebo in combination with pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Why NCT02093962 stopped before completion
NCT02093962 is an interventional study that assigns participants to a tested intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% higher).
The record links to 0 conditions, and to 2 interventions - of which TH-302 combination with pemetrexed is the first listed.
NCT02093962 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02093962 about?
NCT02093962 is a clinical study titled "Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer". The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
What is the current status of trial NCT02093962?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2014-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02093962?
The interventions under investigation include: TH-302 combination with pemetrexed (DRUG), Matched placebo in combination with pemetrexed (DRUG).
Who is sponsoring clinical trial NCT02093962?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02093962's enrollment target sits among peer trials
265 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia